NICE Approves Bevacizumab for Metastatic Colorectal Cancer Following Biosimilar Availability
核心洞察
NICE has published final draft guidance recommending bevacizumab with chemotherapy for metastatic colorectal cancer (搜索), marking the first time the agency has approved this treatment for colorectal cancer (搜索).
More than 7,000 people in England will now have access to this life-extending treatment, made possible by the availability of lower-cost biosimilar versions of the medicine.
Clinical trial evidence demonstrates that bevacizumab plus chemotherapy extends progression-free survival to 9.4 months compared to 8 months with chemotherapy alone, and overall survival to 21.3 months versus 19.9 months.
More than 7,000 people in England will now have access to bevacizumab for advanced bowel cancer (搜索) after NICE published final draft guidance recommending the treatment for metastatic colorectal cancer (搜索). This marks the first time NICE has been able to recommend bevacizumab for colorectal cancer (搜索), following the availability of lower-cost biosimilar versions of the medicine.
Around 35,000 people are diagnosed with colorectal cancer (搜索) in England each year, with nearly 10,000 of those having metastatic colorectal cancer (搜索) where the disease has spread to other parts of the body.
Treatment Mechanism and Clinical Evidence
Bevacizumab, also known by the brand name Avastin, is a targeted treatment that prevents tumors from growing. The drug is administered as an infusion once every two or three weeks alongside chemotherapy.
Clinical trial evidence demonstrates significant benefits when bevacizumab is added to chemotherapy compared with chemotherapy alone. People receiving bevacizumab plus chemotherapy lived without their cancer worsening for 9.4 months on average, compared to 8 months for those having chemotherapy only. Overall survival was 21.3 months compared to 19.9 months for chemotherapy alone.
The treatment is available as both a first and second-line option when targeted treatments or immunotherapy are unsuitable, offering a new choice for patients who would otherwise only receive chemotherapy.
Biosimilars Enable Cost-Effective Access
NICE previously could not recommend bevacizumab for colorectal cancer (搜索) because the branded version of the medicine (Avastin) did not represent value for money for the NHS. However, the availability of more affordable biosimilar versions enabled NICE to conduct a new cost-effectiveness review.
This review was conducted under NICE's Whole Lifecycle Approach to guidance development, which tested a simplified process to develop the recommendation. NICE's whole lifecycle approach is a commitment in the Government's 10-Year Health Plan to continuously review priority clinical pathways, ensuring patients receive the best possible care while the NHS spends wisely.
Helen Knight, director of medicines evaluation at NICE, said: "Assessing the cost-effectiveness of biosimilar medicines is an important step for NICE, allowing us to quickly get effective treatments to patients while ensuring the NHS gets the best value for money. Our Whole Lifecycle Approach means that in cases like this where more affordable versions of treatments become available, we can swiftly re-evaluate medicines that we previously couldn't recommend."
Industry and Government Response
Mark Samuels, Chief Executive of Medicines UK (搜索), which represents off-patent generic and biosimilar medicine suppliers, welcomed the decision: "I am delighted that NICE has recommended bevacizumab for advanced bowel cancer (搜索) because it will help more patients to benefit from this life-extending treatment. I also welcome NICE's use of a new value-for-money process that enables quicker decision-making, as demonstrated in this case."
Samuels emphasized the broader implications: "NICE has a vital role in reassessing treatments as more affordable off-patent biosimilar and generic medicines reshape how we evaluate costs and benefits. With many of the NHS's most expensive medicines being biologics, biosimilars will play an increasingly important role in expanding patient access to proven therapies."
Minister for Women's Health and Mental Health, Baroness Merron, said: "This is excellent news for the thousands of people living with advanced bowel cancer (搜索) who will now have access to this life-extending treatment. The approval demonstrates our commitment to getting patients faster access to treatments and I'm pleased that NICE's new Whole Lifecycle Approach is already delivering results."
The treatment is now available in the NHS.